Pyrazole derivatives of the following formula (I), having affinity for the cannabinoidergic CB1 and/or CB2 receptors:
wherein: R is a group selected from:
C
1
-C
10
alkyl; aryl, arylalkyl or arylalkenyl, not substituted or having from one to four substituents, equal to or different from each other; A is a group selected from the following:
an ether group of formula —(CH
2
)—O—(CH
2
)
v
—R″ wherein v is equal to 1 or 2; R″ is as defined in the present application; a ketone group of formula —C(O)-Z′, wherein Z′ is as defined in the present application; a substituent having an hydroxyl function of formula —CH(OH)-Z′, Z′ being as defined in the present application; Description of the industrial invention in the name of: NEUROSCIENZE S.c. a r.l., of Italian nationality, with head office in Cagliari, via Palabanda 9.
以下式子(I)的吡唑衍生物具有对大麻素受体CB1和/或CB2的亲和力:其中:R是以下组中选择的一组:C1-C10烷基;芳基,芳基烷基或芳基烯基,未取代或具有一个到四个取代基,相互相同或不同;A是以下组中选择的一组:化学式为—(CH2)-O-(CH2)v-R″的醚基,其中v等于1或2;R″如本申请所定义;化学式为—C(O)-Z′的酮基,其中Z′如本申请所定义;具有羟基功能的取代基,化学式为—CH(OH)-Z′,其中Z′如本申请所定义;该工业发明的描述以NEUROSCIENZE S.c. a r.l.的名义进行,该公司是意大利国籍,总部位于卡利亚里,Palabanda 9号。
PYRAZOLE DERIVATIVES HAVING AFFINITY FOR CB1 AND/OR CB2 RECEPTORS
申请人:NEUROSCIENZE PHARMANESS S.C. a R.L.
公开号:EP1602656A1
公开(公告)日:2005-12-07
Pyrazole derivatives of the following formula (I), having affinity for the cannabinoidergic CB1 and/or CB2 receptors:
wherein:
R is a group selected from:
C1-C10 alkyl;
aryl, arylalkyl or arylalkenyl, not substituted or having from one to four substituents, equal to or different from each other;
A is a group selected from the following:
an ether group of formula -(CH2)-O-(CH2)v-R" wherein
- v is equal to 1 or 2;
- R" is as defined in the present application;
a ketone group of formula -C(O)-Z', wherein Z' is as defined in the present application;
a substituent having an hydroxyl function of formula -CH(OH)-Z', Z' being as defined in the present application;
an amide substituent of formula -C(O)-NH-T', T' being as defined in the present application;
B is a group as defined in the present application;
D is an heteroaryl optionally substituted.
对大麻素能 CB1 和/或 CB2 受体具有亲和力的下式 (I) 吡唑衍生物:
其中
R 是选自以下各项的基团
C1-C10 烷基
芳基、芳烷基或芳烯基,未被取代或具有一至四个相互等同或不同的取代基;
A 是选自以下的基团
式中的醚基-(CH2)-O-(CH2)v-R" 其中
- v 等于 1 或 2;
- R "如本申请中所定义;
式-C(O)-Z'的酮基,其中 Z'如本申请中所定义;
式-CH(OH)-Z'的具有羟基官能团的取代基,其中 Z'定义如本申请所 述;
式-C(O)-NH-T'的酰胺取代基,T'如本申请中所定义;
B 是本申请中所定义的基团;
D 是任选取代的杂芳基。
EP1602656B1
申请人:——
公开号:EP1602656B1
公开(公告)日:2011-06-29
PHARMACEUTICAL COMPOUNDS
申请人:Lazzari Paolo
公开号:US20100105896A1
公开(公告)日:2010-04-29
Pyrazole derivatives of the following formula (I), having affinity for the cannabinoidergic CB1 and/or CB2 receptors:
wherein:
R is a group selected from
C
1
-C
10
alkyl;
aryl, arylalkyl or arylalkenyl, not substituted or having from one to four substituents, equal to or different from each other;
A is a group selected from the following:
an ether group of formula —(CH
2
)—O—(CH
2
)
v
—R″ wherein
v is equal to 1 or 2;
R″ is as defined in the present application;
a ketone group of formula —C(O)—Z′, wherein Z′ is as defined in the present application;
a substituent having an hydroxyl function of formula —CH(OH)—Z′, being as defined in the present application; an amide substituent of formula —C(O)—NH-T′, T′ being as defined in the present application;
B is a group as defined in the present application;
D is an heteroaryl optionally substituted.